

---

**From:** Aydin Harston <aharston@rothwellfigg.com>  
**Sent:** Wednesday, August 23, 2017 1:55 PM  
**To:** Hartmann, Anthony  
**Cc:** E. Anthony Figg; LITIGATION PARALEGALS; Livingstone, John; Yoshida, Naoki; toan.vo@bausch.com  
**Subject:** RE: ACRUX DDS PTY LTD. & ACRUX LIMITED v. KAKEN PHARMACEUTICAL CO., LTD. Case IPR2017-00190

Dear Tony,

As you suggested on our call yesterday, we are reviewing the supplemental evidence that Patent Owner served last night to determine whether our concerns have been addressed. When we have completed that review, I will follow up with you if necessary.

Best,  
Aydin

Aydin H. Harston, Ph.D.  
Rothwell, Figg, Ernst & Manbeck PC  
607 14th Street, NW; Suite 800  
Washington, DC 20005  
ph: 202-783-6040  
fax: 202-783-6031

[www.rfem.com](http://www.rfem.com)



The information contained in this electronic message and any attachments to this message are intended for the exclusive use of the addressee(s) and may contain confidential and/or privileged information. If you are not the addressee, note that any disclosure, copy, distribution or use of the contents of this message is prohibited. If you are not the intended recipient, please notify Rothwell, Figg, Ernst & Manbeck P.C. immediately at (202) 783-6040 or email us at [aharston@rfem.com](mailto:aharston@rfem.com), and destroy all copies of this message and any attachments.

---

**From:** Hartmann, Anthony [<mailto:anthony.hartmann@finnegan.com>]  
**Sent:** Wednesday, August 23, 2017 1:13 PM  
**To:** Aydin Harston  
**Cc:** E. Anthony Figg; LITIGATION PARALEGALS; Livingstone, John; Yoshida, Naoki; [toan.vo@bausch.com](mailto:toan.vo@bausch.com)  
**Subject:** ACRUX DDS PTY LTD. & ACRUX LIMITED v. KAKEN PHARMACEUTICAL CO., LTD. Case IPR2017-00190

Dear Aydin,

Further to our conversation of yesterday, we do not understand what additional discovery you are seeking, for which you sought a meet and confer. During the call, you did not provide us with a clear understanding of the full scope of the discovery that Acrux seeks. Once we have a clear understanding of your request for discovery, we can then consult with our clients on this matter before any meet and confer.

We look forward to obtaining some clarification from you.

Regards,  
Tony  
Counsel for Patent Owner

Kaken Exhibit 2202  
Acrux v. Kaken  
IPR2017-00190

**Anthony A. Hartmann**  
Of Counsel

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

901 New York Avenue, NW, Washington, DC 20001-4413

+1 202 408 4275 | fax +1 202 408 4400 | [anthony.hartmann@finnegan.com](mailto:anthony.hartmann@finnegan.com) | [www.finnegan.com](http://www.finnegan.com)

---

**FINNEGAN**

This e-mail message is intended only for individual(s) to whom it is addressed and may contain information that is privileged, confidential, proprietary, or otherwise exempt from disclosure under applicable law. If you believe you have received this message in error, please advise the sender by return e-mail and delete it from your mailbox. Thank you.